Saama Appoints Craig Lipset as Advisor

CAMPBELL, Calif. – Today, life sciences solutions company Saama announced that Craig Lipset has joined the company as Advisor.

As Advisor, Craig will apply his decades of experience in modernizing clinical trials to provide vision and direction for Saama’s continued growth as a global leader in life sciences solutions.

“Craig’s outstanding leadership at the forefront of innovation in clinical research and medicine development will be a tremendous asset in driving Saama’s mission to save and improve more lives,” said Vivek Sharma, Chief Executive Officer of Saama. “We value Craig’s incomparable expertise, vision, and impact, and we are looking forward to our collaborative partnership.”

Craig is the founder of Clinical Innovation Partners, providing growth advisory services for organizations developing and implementing innovative approaches to clinical research and medicine development. He works as an advisor with pharma, biotech, venture capital, and nonprofits to provide vision and drive action at the intersection of research, digital solutions, and patient engagement. 

He is co-chair for the Decentralized Trials & Research Alliance and serves on the Board of Directors for the Foundation for Sarcoidosis Research (Vice President) and the MedStar Health Research Institute (Vice Chair) as well as on the Editorial Board for Therapeutic Innovation & Regulatory Science. In addition, Craig is an Adjunct Assistant Professor in Health Informatics at Rutgers University and an Adjunct Instructor in the Center for Health and Technology at University of Rochester. He also serves on the Advisory Council for HL7 Project Vulcan.

Previously, Craig was the Head of Clinical Innovation and Venture Partner at Pfizer and served on the founding Operations Committee for TransCelerate Biopharma as well as on the founding management teams for two successful startup ventures, Perceptive Informatics and Adnexus Therapeutics. 

About Saama

Saama develops life science solutions that accelerate clinical and commercial development. Today, more than 50 biotech companies—including many of the top 20 pharmaceutical companies—use Saama’s award-winning Life Science Analytics Cloud (LSAC) platform to accelerate more than 1,500 studies, including the clinical trial that led to the world’s first COVID-19 vaccine. LSAC’s rich applications facilitate unprecedented and authoritative oversight and automation of comprehensive clinical research data, enabling companies to file New Drug Applications (NDAs) more efficiently and bring treatments to patients sooner. Discover more at and follow @SaamaTechInc on Twitter.



Victoria Clayton
Gregory FCA
[email protected]